Therapy Areas: Vaccines
Bavarian Nordic secures DKK700m government vaccine contract
9 June 2026 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Tuesday that it has been awarded a government contract valued at more than DKK700m to supply its MVA-BN smallpo...
Anixa secures Canadian patent milestone for ovarian cancer vaccine
1 June 2026 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) reported on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent cover...
Transgene to present preclinical TG-MVA mpox vaccine data at World Congress on Infectious Diseases
26 May 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Tuesday that it will present new preclinical data on its TG-MVA prophylactic vaccine candidates against mpox at the Wor...
4basebio secures clinical supply agreement for Phase II immunotherapy trial
20 May 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) disclosed on Wednesday that it has signed a Clinical Supply Agreement with an unnamed cancer immunotherapy developer to prov...
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
18 May 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that Japan's Ministry of Health, Labour and Welfare has expanded approval for its RSV vaccine, Arexvy, t...
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
12 May 2026 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced late Monday that the US Biomedical Advanced Research and Development Authority (BARDA) has exercised contract opti...